Monthly Archives: July 2023

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

BMB-101 is ahighly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsiesand other indications, such as psychosis, addiction, and impulse control disorders BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending dose and food effects study BMB-101 demonstrated central target engagement and predictable plasma pharmacokinetics  …

Bright Minds Announces Effective Date of Share Consolidation

Vancouver, British Columbia, July 11, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain,announces that, further to its news release on June 22, 2023, the Company will consolidate its common shares (the “CommonShares”)…

Bright Minds Announces Proposed Share Consolidation

Vancouver, British Columbia, June22, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain,announces thatit intends to consolidate its common shares (the “Common shares”) on a five (5) to one (1) basis (the “Consolidation”).…